Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Operating Expenses (2016 - 2025)

ImmunityBio (IBRX) has disclosed Operating Expenses for 12 consecutive years, with $103.0 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 33.81% to $103.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $369.3 million through Dec 2025, up 2.89% year-over-year, with the annual reading at $369.3 million for FY2025, 2.89% up from the prior year.
  • Operating Expenses for Q4 2025 was $103.0 million at ImmunityBio, up from $87.7 million in the prior quarter.
  • The five-year high for Operating Expenses was $111.9 million in Q1 2023, with the low at $77.0 million in Q4 2024.
  • Average Operating Expenses over 5 years is $88.7 million, with a median of $86.3 million recorded in 2021.
  • The sharpest move saw Operating Expenses soared 157.75% in 2021, then fell 15.0% in 2025.
  • Over 5 years, Operating Expenses stood at $79.7 million in 2021, then rose by 6.66% to $85.0 million in 2022, then grew by 0.65% to $85.5 million in 2023, then dropped by 10.03% to $77.0 million in 2024, then skyrocketed by 33.81% to $103.0 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $103.0 million, $87.7 million, and $97.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.